Overview

* Privia Health Group ( PRVA ) Q2 revenue rises 23.4% yr/yr but missed analyst expectations

* Adjusted EBITDA for Q2 beats analyst estimates, reflecting strong operational performance

* Company raises FY 2025 guidance for practice collections and adjusted EBITDA

Outlook

* Privia Health ( PRVA ) raises FY 2025 revenue guidance above high end

* Company expects FY 2025 practice collections above high end

* Privia Health ( PRVA ) sees FY 2025 adjusted EBITDA above high end

* Company anticipates minimal capital expenditures for FY 2025

Result Drivers

* IMPLEMENTED PROVIDERS - Increase of 13.8% in implemented providers compared to 2Q'24

* PRACTICE COLLECTIONS - Practice collections rose 18.5% from 2Q'24

* ADJUSTED EBITDA - Adjusted EBITDA increased by 31.6% compared to 2Q'24

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $521.20 $800.10

Revenue mln mln (12

Analysts

)

Q2 EPS $0.02

Q2 Net $2.70

Income mln

Q2 Beat $29 mln $26.10

Adjusted mln (18

EBITDA Analysts

)

Q2 $3.30

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Privia Health Group Inc ( PRVA ) is $30.00, about 34.1% above its August 6 closing price of $19.78

* The stock recently traded at 72 times the next 12-month earnings vs. a P/E of 84 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)